Analysts Set Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) PT at $25.67

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) has earned an average recommendation of “Buy” from the nine research firms that are currently covering the firm, Marketbeat.com reports. Nine research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have updated their coverage on the stock in […]

Leave a Reply

Your email address will not be published.

Previous post MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $74.50 Consensus Price Target from Analysts
Next post 1,468 Shares in German American Bancorp, Inc. (NASDAQ:GABC) Acquired by KBC Group NV